Suppr超能文献

肝性脑病患者死亡率的预测因素:一项回顾性分析。

Predictors of Mortality in Patients with Hepatic Encephalopathy: A Retrospective Analysis.

作者信息

Iqbal Zafeer-Ul-Hassan, Pervaiz Ayesha, Chaudhry Fatima, Shakeel Zunaira, Hassan Shahzaib, Faiaz Himat Ali, Aleem Shahnoor

机构信息

Internal Medicine, District Headquarter Hospital, Rawalpindi, PAK.

Internal Medicine, Punjab Rangers Teaching Hospital, Lahore, PAK.

出版信息

Cureus. 2025 Jul 10;17(7):e87677. doi: 10.7759/cureus.87677. eCollection 2025 Jul.

Abstract

Background Hepatic encephalopathy (HE) is a serious neuropsychiatric complication of liver dysfunction associated with significant morbidity and mortality. Objective The objective of this study was to evaluate the predictors of in-hospital mortality in patients with HE through retrospective analysis. Methods This retrospective observational cohort study was conducted at Punjab Rangers Teaching Hospital, Lahore, Pakistan, from January 2023 to January 2025. A total of 201 adult patients (≥18 years) admitted with a diagnosis of hepatic encephalopathy were included in the study. The diagnosis of HE was made clinically based on the West Haven criteria and supported by biochemical and radiological assessments as needed. Patients with both acute and chronic liver disease were considered, provided they fulfilled the diagnostic criteria for HE. Data were extracted from the hospital's electronic medical record system using a structured questionnaire. Clinical and laboratory parameters were analyzed to identify predictors of in-hospital mortality using multivariate logistic regression. Results The in-hospital mortality rate was 57 (28.4%). Non-survivors had significantly higher Model for End-Stage Liver Disease (MELD) scores (mean 29.3 vs. 24.9, p < 0.001), elevated serum ammonia levels (mean 136.2 µmol/L vs. 103.1 µmol/L, p < 0.001), more frequent renal dysfunction (37 (64.9%) vs. 41 (28.9%), p < 0.001), and hyponatremia (33 (57.9%) vs. 43 (29.6%), p = 0.002). High-grade HE (Grade III/IV) was more prevalent among non-survivors (42 (73.7%) vs. 52 (36.2%), p < 0.001). Independent predictors of mortality included MELD score ≥28, serum ammonia ≥120 µmol/L, renal dysfunction, serum sodium <130 mEq/L, and high-grade HE. The MELD score demonstrated the highest discriminatory ability (area under the curve (AUC) = 0.78). Conclusion In patients with HE, higher MELD scores, elevated serum ammonia, renal impairment, hyponatremia, and advanced HE grades are significant predictors of mortality. These findings highlight the importance of early risk assessment and may guide decisions regarding intensive management and liver transplant referral.

摘要

背景

肝性脑病(HE)是肝功能障碍的一种严重神经精神并发症,具有较高的发病率和死亡率。

目的

本研究旨在通过回顾性分析评估肝性脑病患者院内死亡的预测因素。

方法

本回顾性观察性队列研究于2023年1月至2025年1月在巴基斯坦拉合尔的旁遮普游骑兵教学医院进行。共有201例诊断为肝性脑病的成年患者(≥18岁)纳入研究。肝性脑病的诊断根据西黑文标准临床做出,并根据需要通过生化和放射学评估予以支持。急性和慢性肝病患者只要符合肝性脑病诊断标准均纳入研究。使用结构化问卷从医院电子病历系统中提取数据。采用多因素逻辑回归分析临床和实验室参数以确定院内死亡的预测因素。

结果

院内死亡率为57例(28.4%)。非存活者终末期肝病模型(MELD)评分显著更高(平均29.3对24.9,p<0.001),血清氨水平升高(平均136.2µmol/L对103.1µmol/L,p<0.001),肾功能不全更常见(37例(64.9%)对41例(28.9%),p<0.001),低钠血症(33例(57.9%)对43例(29.6%),p=0.002)。高级别肝性脑病(III/IV级)在非存活者中更常见(42例(73.7%)对52例(36.2%),p<0.001)。死亡的独立预测因素包括MELD评分≥28、血清氨≥120µmol/L、肾功能不全、血清钠<130mEq/L和高级别肝性脑病。MELD评分显示出最高的鉴别能力(曲线下面积(AUC)=0.78)。

结论

在肝性脑病患者中,较高的MELD评分、血清氨升高、肾功能损害、低钠血症和高级别肝性脑病分级是死亡的重要预测因素。这些发现凸显了早期风险评估的重要性,并可能指导有关强化管理和肝移植转诊的决策。

相似文献

1
Predictors of Mortality in Patients with Hepatic Encephalopathy: A Retrospective Analysis.
Cureus. 2025 Jul 10;17(7):e87677. doi: 10.7759/cureus.87677. eCollection 2025 Jul.
3
L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis.
Cochrane Database Syst Rev. 2018 May 15;5(5):CD012410. doi: 10.1002/14651858.CD012410.pub2.
5
Nutritional support for liver disease.
Cochrane Database Syst Rev. 2012 May 16;2012(5):CD008344. doi: 10.1002/14651858.CD008344.pub2.
8
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
9
Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis.
Cochrane Database Syst Rev. 2023 Jul 19;7(7):CD011585. doi: 10.1002/14651858.CD011585.pub2.

本文引用的文献

4
Acute-on-Chronic Liver Failure in Pregnant Patients with Chronic Hepatitis B: A Retrospective Observational Case Series Study.
Gastroenterol Res Pract. 2020 Aug 12;2020:9831687. doi: 10.1155/2020/9831687. eCollection 2020.
5
Models for acute on chronic liver failure development and mortality in a veterans affairs cohort.
Hepatol Int. 2020 Jul;14(4):587-596. doi: 10.1007/s12072-020-10060-y. Epub 2020 Jun 9.
6
Epidemiology of Hepatic Encephalopathy.
Clin Liver Dis. 2020 May;24(2):157-174. doi: 10.1016/j.cld.2020.01.001. Epub 2020 Mar 2.
7
Incidence of and Risk Factors for Hepatic Encephalopathy in a Population-Based Cohort of Americans With Cirrhosis.
Hepatol Commun. 2019 Sep 6;3(11):1510-1519. doi: 10.1002/hep4.1425. eCollection 2019 Nov.
8
Association of serum albumin level with incidence and mortality of overt hepatic encephalopathy in cirrhosis during hospitalization.
Therap Adv Gastroenterol. 2019 Oct 7;12:1756284819881302. doi: 10.1177/1756284819881302. eCollection 2019.
9
Albumin infusion may decrease the incidence and severity of overt hepatic encephalopathy in liver cirrhosis.
Aging (Albany NY). 2019 Oct 8;11(19):8502-8525. doi: 10.18632/aging.102335.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验